Clinical Trials Browser

Phase 1 × Brentuximab Vedotin × Dermatologic × Clear all

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

16 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1 Terminated

133 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03373305 2019-04-30

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Clinical Trials

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

EpiBrentlen

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas